Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities.

Saved in:
Bibliographic Details
Title: Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities.
Authors: Estadt AT; College of Public Health, Division of Epidemiology, Ohio State University, 1841 Neil Avenue, Columbus, OH, 43210, USA. estadt.24@osu.edu., Kline D; Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Miller WC; Gillings School of Global Public Health, Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Feinberg J; Departments of Behavioral Medicine and Psychiatry & Medicine/Infectious Diseases, West Virginia University School of Medicine, Morgantown, WV, USA., Hurt CB; Institute for Global Health & Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Mixson LS; Department of Medicine, University of Washington, Seattle, WA, USA., Friedmann PD; University of Massachusetts Medical School-Baystate and Baystate Health, Springfield, MA, USA., Lowe K; Department of Medicine, Division of Infectious Disease, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA., Tsui JI; Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA., Young AM; Department of Epidemiology, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, USA., Cooper H; Rollins School of Public Health, Emory University, Atlanta, GA, USA., Korthuis PT; Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA., Pho MT; Department of Medicine, University of Chicago, Chicago, IL, USA., Jenkins W; Department of Public Health Sciences, Clemson University, Clemson, SC, USA., Westergaard RP; Department of Medicine, Division of Infectious Disease, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA., Go VF; Gillings School of Global Public Health, Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Brook D; College of Medicine, Ohio State University, Columbus, OH, USA., Smith G; Department of Epidemiology and Biostatistics, West Virginia University School of Public Health, Morgantown, WV, USA., Rice DR; University of Massachusetts Chan School of Medicine, Worcester, MA, USA., Lancaster KE; Division of Public Health Sciences, Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Source: Harm reduction journal [Harm Reduct J] 2024 Nov 29; Vol. 21 (1), pp. 214. Date of Electronic Publication: 2024 Nov 29.
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101153624 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7517 (Electronic) Linking ISSN: 14777517 NLM ISO Abbreviation: Harm Reduct J Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1477-7517
DOI:10.1186/s12954-024-01131-6